Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
It’s been quite a week with some big scoops from the Endpoints team, on top of what is shaping up to be an interesting earnings season. See you next week as we track the biggest themes emerging from media and investor calls.
Bristol Myers eyes major cuts
About five months into his tenure as Bristol Myers Squibb CEO, Chris Boerner unveiled plans for $1.5 billion in cost-cutting measures, including changes to the pipeline and a workforce reduction of 2,200 by the end of the year. “About 12” programs are getting swept out of the pipeline, and…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
